Original Research Article
Asthma Drugs and the Risk of Congenital Anomalies
Article first published online: 28 FEB 2013
© 2013 Pharmacotherapy Publications, Inc
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Volume 33, Issue 4, pages 363–368, April 2013
How to Cite
Vasilakis-Scaramozza, C., Aschengrau, A., Cabral, H. J. and Jick, S. S. (2013), Asthma Drugs and the Risk of Congenital Anomalies. Pharmacotherapy, 33: 363–368. doi: 10.1002/phar.1213
- Issue published online: 1 APR 2013
- Article first published online: 28 FEB 2013
- congenital anomalies;
- prevalence rates;
- relative risk
To estimate the prevalence of congenital anomalies between the offspring of women exposed and unexposed to asthma drugs during early pregnancy.
Matched cohort study.
The United Kingdom's General Practice Research Database.
Women exposed to asthma drugs during early pregnancy and a sample of matched unexposed pregnant women.
Measurements and Main Results
The prevalence of any anomaly among unexposed and exposed women was 27.8 (95% confidence interval [CI] 25.4–30.6)/1000 pregnancies and 31.3 (95% CI 27.7–35.5)/1000 pregnancies, respectively (relative risk [RR] 1.1 95% CI 1.0–1.3).
Our findings suggest that asthma drugs, overall, do not increase the risk of congenital anomalies in the offspring when taken during the first trimester of pregnancy.